InfuSystems (INFU) vs Standard BioTools (LAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
InfuSystems (INFU) has outperformed Standard BioTools (LAB) over the past year, gaining 31.1% versus a loss of 47.8%. Over five years, INFU leads with a +3.6% price change compared with -87.3% for LAB. Standard BioTools is the larger company by market cap ($266.4 million vs $265.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INFU | LAB |
|---|---|---|
| Share price | $13.33 | $0.6787 |
| Market cap | $265.50M | $266.44M |
| 1-day change | +0.45% | -6.00% |
| YTD return | +48.61% | -46.98% |
| 1-year return | +31.07% | -47.79% |
| 5-year return | +3.57% | -87.29% |
| P/E ratio (TTM) | 33.33 | — |
| Forward P/E | 25.63 | — |
| EPS (TTM) | $0.40 | $-0.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.85 | $1.72 |
| 52-week low | $7.29 | $0.63 |
| Distance from 52-week high | -3.75% | -60.54% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +26.26% | +98.91% |
| Average volume | 141.49K | 1.57M |
| Shares outstanding | 19.92M | 392.58M |
| Employees | 461 | 385 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INFU has outperformed LAB by 78.9 percentage points over the past year.
About InfuSystems
INFU stock →InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates through two segments: Patient Services and Device Solutions.
Healthcare · Medical Devices · 461 employees
About Standard BioTools
LAB stock →Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.
Healthcare · Medical Devices · 385 employees
INFU vs LAB FAQ
Which is bigger, InfuSystems or Standard BioTools?
Standard BioTools (LAB) is larger, with a market capitalization of $266.44M compared with $265.50M for InfuSystems (INFU).
Which stock has performed better over the past year, INFU or LAB?
INFU returned +31.07% over the past 12 months, compared with -47.79% for LAB (price return, excluding dividends). Past performance does not predict future results.
Are InfuSystems and Standard BioTools in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.